Stifel Financial’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Stifel Financial’s Portfolio TTPH Stock Details TTPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-719	Closed	-$91K	–	2802
2017 Q4	$91K	Buy	+719	New	+$92.1K	﹤0.01%	2558
2015 Q3	–	Sell	-743	Closed	-$705K	–	2413
2015 Q2	$705K	Buy	743 +332	+81%	+$271K	﹤0.01%	1510
2015 Q1	$301K	Buy	+411	New	+$309K	﹤0.01%	1899

Other funds holding TTPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Stifel Financial's TTPH Position: Q1 2018 in Review

Stifel Financial sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q1 2018, closing a stake of 719 shares — an estimated $91K sold.

Stifel Financial first reported a position in TTPH in Q1 2015 and held it in 3 quarters. The position peaked at $705K in Q2 2015. 94 funds tracked by Wall St. Rank hold TTPH as of Q1 2018.

Stifel Financial reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
Stifel Financial sold 719 Tetraphase Pharmaceuticals, Inc. shares in Q1 2018, an estimated $91K.
Stifel Financial first reported a position in Tetraphase Pharmaceuticals, Inc. in Q1 2015 and held it in 3 quarters.
Stifel Financial's Tetraphase Pharmaceuticals, Inc. position peaked at $705K in Q2 2015.
94 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q1 2018.

Based on Stifel Financial's 13F filing for Q1 2018, filed 11 May 2018.